Effect of Diltiazem Administration on CP-945,598 Pharmacokinetics
NCT00645463
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
Adult Trials: 18+ Years
- No clinically relevant abnormalities based upon medical history, physical exam, 12-lead ECG, and clinical lab tests
- Body Mass Index (BMI) ~ 27-40 kg/m2, inclusive
- Personally signed inform consent document
- Evidence or history of significant acute or chronic disease
- Pregnant or nursing females
- Screening PR interval > 220 msec
- Sitting blood pressure <= 90 mmHg systolic or <= 60 mmHg diastolic
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Albany, New York
- Petach Tikva,
- New Haven, Connecticut
- Birmingham, Alabama
- Birmingham, Alabama
- Huntsville, Alabama
- Mobile, Alabama
- Chandler, Arizona
- Mesa, Arizona
- Phoenix, Arizona
- Fresno, California
- Palm Springs, California
- Tustin, California
- Walnut Creek, California
- New Britain, Connecticut
- Washington, District of Columbia
- Orlando, Florida
- West Palm Beach, Florida
- Honolulu, Hawaii
- Gurnee, Illinois
- Madisonville, Kentucky
- Baton Rouge, Louisiana
- Metairie, Louisiana
- Auburn, Maine
- Scarborough, Maine
- Baltimore, Maryland
- Bay City, Michigan
- Troy, Michigan
- Edina, Minnesota
- Jefferson City, Missouri
- Albuquerque, New Mexico
- Buffalo, New York
- New York, New York
- Greenville, North Carolina
- Beaver, Pennsylvania
- Cumberland, Rhode Island
- Pawtucket, Rhode Island
- Greer, South Carolina
- Bristol, Tennessee
- Nashville, Tennessee
- Dallas, Texas
- Dallas, Texas
- San Antonio, Texas
- San Antonio, Texas
- Renton, Washington
- Morgantown, West Virginia
- Buenos Aires,
- Buenos Aires,
- Buenos Aires,
- Garran, Australian Capital Territory
- Wollongong, New South Wales
- Adelaide, South Australia
- Box Hill, Victoria
- Nedlands, Western Australia
- Curitiba, PR
- Porto Alegre, RS
- São Paulo, SP
- São Paulo, SP
- São Paulo, SP
- São Paulo, SP
- Red Deer, Alberta
- Coquitlam, British Columbia
- Winnipeg, Manitoba
- Thornhill, Ontario
- Charlottetown, Prince Edward Island
- L'Ancienne-Lorette, Quebec
- Saint-Marc-des-Carrières, Quebec
- Breclav,
- Ceske Budejovice,
- Olomouc,
- Praha 2,
- Praha 4 - Krc,
- Berlin,
- Dresden,
- Duesseldorf,
- Hamburg,
- Leipzig,
- Mittweida,
- Tampico, Cd. Madero
- Mexico, DF
- Guadalajara, Jalisco
- Monterrey, Nuevo León
- Banska Bystrica,
- Bratislava,
- Lubochna,
- Nitra,
- Goteborg,
- Huddinge,
- Edinburgh, Lothian
- Bath, Somerset
- Coventry,
- Dumfries,
- Dundee,
- Luton,
| Descriptive Information | ||||
|---|---|---|---|---|
| Brief Title ICMJE | Effect of Diltiazem Administration on CP-945,598 Pharmacokinetics | |||
| Official Title ICMJE | A Phase 1, Randomized, Fixed Sequence Study To Evaluate The Effect Of Multiple Dose Administration Of Modified Release Diltiazem On The Multiple Dose Pharmacokinetics Of CP-945,598 In Healthy Overweight And Obese Subjects | |||
| Brief Summary | A recently completed clinical drug interaction study of CP-945,598 with ketoconazole, a potent CYP3A inhibitor, showed that coadministration of CP-945,598 with ketoconazole results in an approximately 5-fold increase in CP-945,598 total exposure (AUC) and 4-fold increase in Cmax. Therefore, the sensitivity of CP-945,598 pharmacokinetics (PK) to less potent CYP3A inhibitors needs to be characterized to support labeling and registration. Diltiazem is a known substrate and moderate mechanism-based inhibitor of the CYP3A enzyme system and was chosen as the moderate CYP3A inhibitor for this study as it is a clinically relevant medication likely to be prescribed concomitantly with CP-945,598 given the increased risk of hypertension and cardiovascular disease in the obese patient population. | |||
| Detailed Description | Not Provided | |||
| Study Type ICMJE | Interventional | |||
| Study Phase ICMJE | Phase 1 | |||
| Study Design ICMJE | Allocation: Randomized Intervention Model: Crossover Assignment Masking: None (Open Label) Primary Purpose: Treatment | |||
| Condition ICMJE | Obesity | |||
| Intervention ICMJE |
| |||
| Study Arms ICMJE |
| |||
| Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
| Recruitment Information | ||||
| Recruitment Status ICMJE | Completed | |||
| Actual Enrollment ICMJE | 28 | |||
| Original Actual Enrollment ICMJE | Same as current | |||
| Actual Study Completion Date ICMJE | June 2007 | |||
| Primary Completion Date | Not Provided | |||
| Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
| Sex/Gender ICMJE |
| |||
| Ages ICMJE | 18 Years to 55 Years (Adult) | |||
| Accepts Healthy Volunteers ICMJE | Yes | |||
| Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
| Listed Location Countries ICMJE | United States | |||
| Removed Location Countries | ||||
| Administrative Information | ||||
| NCT Number ICMJE | NCT00645463 | |||
| Other Study ID Numbers ICMJE | A5351043 | |||
| Has Data Monitoring Committee | No | |||
| U.S. FDA-regulated Product | Not Provided | |||
| IPD Sharing Statement ICMJE | Not Provided | |||
| Responsible Party | Director, Clinical Trial Disclosure Group, Pfizer, Inc. | |||
| Study Sponsor ICMJE | Pfizer | |||
| Collaborators ICMJE | Not Provided | |||
| Investigators ICMJE |
| |||
| PRS Account | Pfizer | |||
| Verification Date | March 2008 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP | ||||